Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Next Previous
X
Search
Trial Profile

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Obesity; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 28 Nov 2024 According to a Novo Nordisk a media release, Wegovy (semaglutide injection) is now approved to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI equal to or greater than 27 kg/m2. Health Canada's non-fatal MI indication for Wegovy is based on results of this trial.
    • 18 Nov 2024 Results assessing efficacy presented at the American Heart Association Scientific Sessions 2024
    • 06 Sep 2024 According to a Novo Nordisk a media release, data from this trial to be presented at the upcoming 60th Annual Meeting of the European Association for the Study of Diabetes (EASD), which will take place in Madrid, Spain Sep 9-13, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top